A dominant antigen is necessary but not sufficient for effective neoantigen vaccination in murine mesothelioma

Coverage, in order

1. 13h ago
   Research Square obscure study

   A dominant antigen is necessary but not sufficient for effective neoantigen vaccination in murine mesothelioma

   Neoantigen vaccines have emerged as a promising strategy for personalised cancer treatment, however the features of neoantigen vaccines that confer effective tumour protection remain poorly defined. Further, their application for low tumour mutation burden (TMB) cancers has been largely unexplored…

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.